CompletedPhase 2

Urinary Excretion of Acetylamantadine by Cancer Patients

Canada150 participantsStarted 2003-12

Plain-language summary

The investigators have determined that the drug amantadine hydrochloride is metabolized by acetylation by a specific enzyme named spermidine/spermine N-acetyltransferase (SSAT). This enzyme is increased in cancer cells. The investigators hypothesized that the amount of N-acetylamantadine excreted in urine during the first 12 hours after an oral dose would serve as a diagnostic biomarker for the presence of cancer in a human test subject.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Either a medical diagnosis of cancer, or determination of general good health after a medical check-up within two weeks of participation in the study Exclusion Criteria: * Allergy to amantadine hydrochloride * Chronic liver or kidney disease * Chronic disease state not controlled by drug therapy, e.g. hypertension * Pregnancy

What they're measuring

Amount of N-acetylamantadine excreted in a 12 hour urine sample collected after a single oral dose of amantadine hydrochloride ingested two hours after supper

Timeframe: 12 hours

Trial details

NCT IDNCT00755898

SponsorUniversity of Manitoba

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-06

View on ClinicalTrials.gov More Cancer trials